drugset / Trial / NCT00834132
Azithromycin 600 Mg Tablets, Fed
RandomizedCrossoverOpen-labelOther
Summary
The objective of this randomized, single-dose, two-way crossover evaluation is to compare the relative bioequivalence of a test azithromycin formulation (TEVA Pharmaceuticals USA) to an equivalent oral dose of the commercially available azithromycin (Zithromax®, Pfizer, Inc.) in a test population of 24 adult subjects under fed conditions.
Timeline
- Start
- 2002-07
- Primary completion
- 2002-08
- Completion
- 2002-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azithromycin | Small molecule | 600 mg | Oral |
Indications
No indication recorded.